v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Total revenues $ 15,388 $ 14,503
Expenses:    
Research and development [1] 11,452 8,968
Selling, general and administrative [1] 18,370 16,742
Total expenses 29,822 25,710
Loss from operations (14,434) (11,207)
Interest expense (non-cash) (643) (629)
Interest and other income, net 939 1,434
Loss before income taxes (14,138) (10,402)
Provision for income tax benefit (expense) 559 (1,262)
Net loss (13,579) (11,664)
Other comprehensive income (loss):    
Net unrealized gain (loss) on available-for-sale investments, net of tax (7) 24
Comprehensive loss $ (13,586) $ (11,640)
Net loss per share:    
Net loss per share - basic (in dollars per share) $ (0.27) $ (0.24)
Net loss per share - diluted (in dollars per share) $ (0.27) $ (0.24)
Shares used to compute net loss per share - basic 49,706 48,283
Shares used to compute net loss per share - diluted 49,706 48,283
Viatris collaboration agreement    
Revenues:    
Total revenues $ 15,388 $ 14,503
[1] Amounts include share-based compensation expense as follows: